#TeamVernunft #ImpfenSchützt #Borelliose #Impfung #Zecken #EMA
Inzwischen neuer Stand zu #PF-07307405:
Inzwischen neuer Stand zu #PF-07307405:
Ja, der Zulassungsantrag wurde sogar inzwischen von der EMA validiert:
PF-07307405
www.pharmaceutical-technology.com/news/ema-pfi...
www.biopharminternational.com/view/ema-val...
Dauert also voraussichtlich nicht mehr lange, dann kann endlich geimpft werden.
PF-07307405
www.pharmaceutical-technology.com/news/ema-pfi...
www.biopharminternational.com/view/ema-val...
Dauert also voraussichtlich nicht mehr lange, dann kann endlich geimpft werden.
EMA Validates Marketing Authorization Application for Pfizer/Valneva's Lyme Disease Vaccine Candidate | BioPharm International
The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, Pfizer and Valneva's six-valent OspA-based Lyme disease vaccine candidate, beginning formal review ...
www.biopharminternational.com
August 28, 2026 at 12:13 AM
#TeamVernunft #ImpfenSchützt #Borelliose #Impfung #Zecken #EMA
Inzwischen neuer Stand zu #PF-07307405:
Inzwischen neuer Stand zu #PF-07307405:
Source:
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial | Pfizer
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi...
www.pfizer.com
March 23, 2026 at 9:36 PM
Source:
Ja, der Zulassungsantrag wurde sogar inzwischen von der EMA validiert:
PF-07307405
www.pharmaceutical-technology.com/news/ema-pfi...
www.biopharminternational.com/view/ema-val...
Dauert also voraussichtlich nicht mehr lange, dann kann endlich geimpft werden.
PF-07307405
www.pharmaceutical-technology.com/news/ema-pfi...
www.biopharminternational.com/view/ema-val...
Dauert also voraussichtlich nicht mehr lange, dann kann endlich geimpft werden.
EMA Validates Marketing Authorization Application for Pfizer/Valneva's Lyme Disease Vaccine Candidate | BioPharm International
The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, Pfizer and Valneva's six-valent OspA-based Lyme disease vaccine candidate, beginning formal review ...
www.biopharminternational.com
August 27, 2026 at 11:50 PM
Ja, der Zulassungsantrag wurde sogar inzwischen von der EMA validiert:
PF-07307405
www.pharmaceutical-technology.com/news/ema-pfi...
www.biopharminternational.com/view/ema-val...
Dauert also voraussichtlich nicht mehr lange, dann kann endlich geimpft werden.
PF-07307405
www.pharmaceutical-technology.com/news/ema-pfi...
www.biopharminternational.com/view/ema-val...
Dauert also voraussichtlich nicht mehr lange, dann kann endlich geimpft werden.
“Der Impfstoffkandidat PF-07307405 zeigte in der jüngsten Studienphase bei Menschen ab fünf Jahren eine Wirksamkeit von mehr als 70 Prozent gegen Lyme-Borreliose.”
May 24, 2026 at 6:02 AM
“Der Impfstoffkandidat PF-07307405 zeigte in der jüngsten Studienphase bei Menschen ab fünf Jahren eine Wirksamkeit von mehr als 70 Prozent gegen Lyme-Borreliose.”
Pfizer and Valneva's Lyme disease vaccine shows 73.2% efficacy in phase 3 trials, increasing the potential for it to become the first approved vaccine for human use. The vaccine targets Borrelia bacteria, offering significant preventive potential against Lyme disease.
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial | Pfizer
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi...
www.pfizer.com
May 14, 2026 at 2:16 AM
Pfizer and Valneva's Lyme disease vaccine shows 73.2% efficacy in phase 3 trials, increasing the potential for it to become the first approved vaccine for human use. The vaccine targets Borrelia bacteria, offering significant preventive potential against Lyme disease.
Čtyřdávkové schéma není ideální, ale snad už brzy budeme (opět) mít vakcínu proti lymské borelióze.
(Jedna už byla na trhu v 90. letech, ale výrobce ji stáhl z trhu kvůli mediálním (nepodloženým) podezřením na nežádoucí účinky.)
(Jedna už byla na trhu v 90. letech, ale výrobce ji stáhl z trhu kvůli mediálním (nepodloženým) podezřením na nežádoucí účinky.)
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial | Pfizer
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi...
www.pfizer.com
June 3, 2026 at 7:35 AM
Čtyřdávkové schéma není ideální, ale snad už brzy budeme (opět) mít vakcínu proti lymské borelióze.
(Jedna už byla na trhu v 90. letech, ale výrobce ji stáhl z trhu kvůli mediálním (nepodloženým) podezřením na nežádoucí účinky.)
(Jedna už byla na trhu v 90. letech, ale výrobce ji stáhl z trhu kvůli mediálním (nepodloženým) podezřením na nežádoucí účinky.)
Lyme vaccine news. I want this. Both my kids were in the phase 3 trial.
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial | Pfizer
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi...
www.pfizer.com
March 23, 2026 at 9:28 PM
Lyme vaccine news. I want this. Both my kids were in the phase 3 trial.
Vive la science !!! www.pfizer.com/news/press-r...
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial | Pfizer
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi...
www.pfizer.com
March 24, 2026 at 3:05 AM
Vive la science !!! www.pfizer.com/news/press-r...
Aşı adayı PF-07307405, bakterinin dış yüzeyindeki bir proteini hedefleyerek bağışıklık sistemini harekete geçiriyor ve antikor üretimini sağlıyor. Özellikle doğada vakit geçiren kişiler için böyle bir aşının önemli bir koruma sağlayabileceği düşünülüyor.
May 6, 2026 at 5:46 AM
Aşı adayı PF-07307405, bakterinin dış yüzeyindeki bir proteini hedefleyerek bağışıklık sistemini harekete geçiriyor ve antikor üretimini sağlıyor. Özellikle doğada vakit geçiren kişiler için böyle bir aşının önemli bir koruma sağlayabileceği düşünülüyor.
📢 #Pfizer and #Valneva Announce that #LymeDisease 🕷️ #Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial:
www.pfizer.com/news/press-r...
www.pfizer.com/news/press-r...
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial | Pfizer
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi...
www.pfizer.com
June 26, 2026 at 11:04 PM
📢 #Pfizer and #Valneva Announce that #LymeDisease 🕷️ #Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial:
www.pfizer.com/news/press-r...
www.pfizer.com/news/press-r...
Lyme disease vaccine candidate showed almost 75% efficacy in Phase 3 trials. Finally, a way to prevent this debilitating tick-borne illness!
Lyme Disease Vaccine Candidate Shows High Efficacy in Phase 3 Trial, Paving Way for Regulatory Submi
Pfizer Inc. and Valneva SE have announced positive topline results from their Phase 3 clinical trial for an investigational 6-valent OspA-based Lyme disease vaccine candidate, PF-07307405 (LB6V). The
www.vax-before-travel.com
March 30, 2026 at 8:02 PM
Lyme disease vaccine candidate showed almost 75% efficacy in Phase 3 trials. Finally, a way to prevent this debilitating tick-borne illness!
Lyme vaccine news: A Pfizer/Valneva vaccine candidate had 73-75% efficacy in trials. How might this change outdoor activities if it's approved?
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 V
A Lyme disease vaccine candidate, PF-07307405 (LB6V), developed by Pfizer and Valneva, has shown strong efficacy in its Phase 3 clinical trial. The investigational vaccine proved effective in preventi
valneva.com
March 24, 2026 at 2:05 PM
Lyme vaccine news: A Pfizer/Valneva vaccine candidate had 73-75% efficacy in trials. How might this change outdoor activities if it's approved?
Vielleicht auch nur ein entzündeter Stich...da drück ich mal die Daumen. Wobei der Ring schon recht aussagekräftig is.
Hast du das schon gesehen? Werd mir den sofort genehmigen, wenn er da ist.
Hast du das schon gesehen? Werd mir den sofort genehmigen, wenn er da ist.
Neuer Impfstoffkandidat gegen Borreliose zeigt gute Wirksamkeit - Deutsche Apotheker Zeitung
Der von Pfizer und Valneva entwickelte Impfstoffkandidat PF-07307405 gegen Lyme-Borreliose schützt zuverlässig vor der Infektionserkrankung.
www.deutsche-apotheker-zeitung.de
August 4, 2026 at 9:15 AM
Vielleicht auch nur ein entzündeter Stich...da drück ich mal die Daumen. Wobei der Ring schon recht aussagekräftig is.
Hast du das schon gesehen? Werd mir den sofort genehmigen, wenn er da ist.
Hast du das schon gesehen? Werd mir den sofort genehmigen, wenn er da ist.
There was a "promising" vaccine, but it failed the Phase III threshold. It's funny to see the Pfizer press release vs a third-party website article. (1/2)
Pfizer:
Pfizer:
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial | Pfizer
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi...
www.pfizer.com
April 29, 2026 at 5:59 PM
There was a "promising" vaccine, but it failed the Phase III threshold. It's funny to see the Pfizer press release vs a third-party website article. (1/2)
Pfizer:
Pfizer:
Did a look around, and and the trial is actually over now. The vaccine is fairly effective, though far from perfect. It's not approved yet, so you can't actually get it.
Not clear to me whether the current FDA will approve it, simply because they hate vaccines.
www.pfizer.com/news/press-r...
Not clear to me whether the current FDA will approve it, simply because they hate vaccines.
www.pfizer.com/news/press-r...
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial | Pfizer
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi...
www.pfizer.com
May 19, 2026 at 7:42 PM
Did a look around, and and the trial is actually over now. The vaccine is fairly effective, though far from perfect. It's not approved yet, so you can't actually get it.
Not clear to me whether the current FDA will approve it, simply because they hate vaccines.
www.pfizer.com/news/press-r...
Not clear to me whether the current FDA will approve it, simply because they hate vaccines.
www.pfizer.com/news/press-r...
I missed this in March. Two phase-3 trials completed for a Lyme disease vaccine that they think is about 75% effective
Now we just need to pray that the CDC lets it through because I dunno about you, but to me anything's better than "just check for ticks."
www.pfizer.com/news/press-r...
Now we just need to pray that the CDC lets it through because I dunno about you, but to me anything's better than "just check for ticks."
www.pfizer.com/news/press-r...
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial | Pfizer
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi...
www.pfizer.com
May 21, 2026 at 11:27 AM
I missed this in March. Two phase-3 trials completed for a Lyme disease vaccine that they think is about 75% effective
Now we just need to pray that the CDC lets it through because I dunno about you, but to me anything's better than "just check for ticks."
www.pfizer.com/news/press-r...
Now we just need to pray that the CDC lets it through because I dunno about you, but to me anything's better than "just check for ticks."
www.pfizer.com/news/press-r...
March 23, 2026 at 11:27 PM
After reporting mixed clinical results in a phase 3 trial, #Pfizer and #Valneva have filed their #Lymedisease #vaccinecandidate PF-07307405 in the #EU, and the #EMA has started its #review.
buff.ly/juuf1HL
buff.ly/juuf1HL
Pfizer, Valneva Lyme vaccine starts review in Europe
After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU.
pharmaphorum.com
August 14, 2026 at 2:49 PM
After reporting mixed clinical results in a phase 3 trial, #Pfizer and #Valneva have filed their #Lymedisease #vaccinecandidate PF-07307405 in the #EU, and the #EMA has started its #review.
buff.ly/juuf1HL
buff.ly/juuf1HL
Anyone who lives in or near Appalachia should be excited! As a study participant, it’s cool to see the vaccine close to becoming available to the public. Especially for a problem that plagues so many 🦠
The First Lyme Disease Vaccine in 24 Years Just Passed Its Pivotal Phase 3 Trial with 74 Percent Efficacy — and It Is for Children Too
Pfizer and Valneva announced Phase 3 VALOR trial results for Lyme disease vaccine PF-07307405 on March 23, 2026: 73.2–74.8% efficacy in ages 5 and older. Regulatory submissions planned for 2026. No Ly...
www.medicaldaily.com
July 14, 2026 at 2:50 PM
Anyone who lives in or near Appalachia should be excited! As a study participant, it’s cool to see the vaccine close to becoming available to the public. Especially for a problem that plagues so many 🦠
Malattia di Lyme: forte efficacia del vaccino PF-07307405 (LB6V) nello studio di fase 3 VALOR
Pfizer Inc. e Valneva SE hanno annunciato oggi i risultati preliminari dello studio clinico di Fase 3 VALOR "Vaccino contro la malattia di Lyme per gli appassionati di attività ricreative all'aperto" (…
Pfizer Inc. e Valneva SE hanno annunciato oggi i risultati preliminari dello studio clinico di Fase 3 VALOR "Vaccino contro la malattia di Lyme per gli appassionati di attività ricreative all'aperto" (…
Malattia di Lyme: forte efficacia del vaccino PF-07307405 (LB6V) nello studio di fase 3 VALOR
Pfizer Inc. e Valneva SE hanno annunciato oggi i risultati preliminari dello studio clinico di Fase 3 VALOR "Vaccino contro la malattia di Lyme per gli appassionati di attività ricreative all'aperto" ( NCT05477524 ) del suo candidato vaccino sperimentale esavalente contro la malattia di Lyme basato su OspA PF-07307405 (LB6V, precedentemente noto come VLA15) che dimostra: Nelle analisi predefinite: Efficacia del 73,2% a partire da 28 giorni dopo la quarta dose (stagione 2) nella riduzione del tasso di casi confermati di malattia di Lyme rispetto al gruppo placebo (IC 95% 15,8, 93,5)
www.salutedomani.com
March 24, 2026 at 2:16 PM
Malattia di Lyme: forte efficacia del vaccino PF-07307405 (LB6V) nello studio di fase 3 VALOR
Pfizer Inc. e Valneva SE hanno annunciato oggi i risultati preliminari dello studio clinico di Fase 3 VALOR "Vaccino contro la malattia di Lyme per gli appassionati di attività ricreative all'aperto" (…
Pfizer Inc. e Valneva SE hanno annunciato oggi i risultati preliminari dello studio clinico di Fase 3 VALOR "Vaccino contro la malattia di Lyme per gli appassionati di attività ricreative all'aperto" (…